BALTIMORE--(BUSINESS WIRE)--TNF Pharmaceuticals, Inc. (Nasdaq: TNFA) (“TNF” or the “Company”), a clinical stage biopharmaceutical company committed to developing novel therapies for autoimmune and ...
Positive clinical data validates current Phase 2b clinical trial of isomyosamine as a treatment for chronic inflammation associated with muscle loss The presentation included positive Phase 2a ...
Positive clinical data validates commencement of a larger Phase 2b clinical trial in elderly patients post-hip fracture Drug shown to decrease biomarkers associated with TNF-alpha activation in ...
Transformative potential for novel TNF-alpha inhibitor drug: Estimated $40 billion TNF inhibitor market and $50 billion GLP-1 agonist market BALTIMORE--(BUSINESS WIRE)-- TNF Pharmaceuticals, Inc.
Tumour necrosis factor (TNF)‑alpha inhibitors are recommended as treatment options for people with severe rheumatoid arthritis (disease activity score [DAS28] greater than 5.1) whose disease does not ...
NEW YORK--(BUSINESS WIRE)--TNF Pharmaceuticals, Inc. (Nasdaq: TNFA) (“TNF” or the “Company”), a clinical stage biopharmaceutical company committed to developing novel therapies for autoimmune and ...
The authors of a review in Clinical and Experimental Dermatology assessed the association between long-term TNF-α inhibitor (TNFi) therapy and the risk of cancer among 32,765 patients with psoriasis.
Potential entry into high growth GLP-1 market of nearly $50 billion in 2024, projected value of $100 billion by 2029 BALTIMORE--(BUSINESS WIRE)-- TNF Pharmaceuticals, Inc. (Nasdaq: TNFA) (“TNF” or the ...
Biologics remain viable options with varying persistence over 1 year in patients with inflammatory bowel disease.
The assessment compared 6 intervention tests (enzyme-linked immunosorbent assay [ELISA] tests: Promonitor, IDKmonitor, LISA‑TRACKER, RIDASCREEN, MabTrack, and in-house tests used by Sanquin Diagnostic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback